Trial Profile

A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Targeting Patient-unique Tumor-specific Neoantigens, With in Vivo CD40 Activation and PD-1 Blockade, for Patients With Incurable Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CDX 1140 (Primary) ; Pembrolizumab (Primary) ; TCR T cell therapy (Primary)
Indications Cancer
Focus Adverse reactions

26 Oct 2024 Status changed from recruiting to active, no longer recruiting.
02 Jun 2023 Planned End Date changed from 15 Mar 2028 to 15 Apr 2028.
02 Jun 2023 Planned primary completion date changed from 15 Mar 2026 to 15 Apr 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com